The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropion + varenicline in rats.

"The technical assistance provided by Rosita Stomberg is gratefully acknowledged. This work was financially supported by the Swedish Medical Research Council (2020-01346 and 2020-02105), the Swedish Brain Foundation, governmental support under the LUA/ALF agreement, Göteborgs Läkaresällskap (GLS-985839 and GLS-960721), Fredrik och Ingrid Thurings Stiftelse (2020-00607), Systrarna Greta Johanssons och Brita Anderssons minnesfond, Bror Gadelius Minnesfond and Stiftelsen Wilhelm och Martina Lundgrens vetenskapsfond (2022-4085). BS, ME and HL are co-owners of Sobrera Pharma AB that has filed for a patent for using the combination of the drugs here investigated in the treatment of AUD. BS, ME, YO and three other researchers are co-inventors of this patent. All other authors declare no conflict of interest."

"Funding Open access funding provided by University of Gothenburg."